FindTrial
Sign In

Identification of aberrant promoter methylation in liver cancer

Identification of aberrant promoter methylation in liver cancer - Identification of aberrant promoter methylation in liver cancer

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000001317
Enrollment
300
Registered
2008-09-10
Start date
2005-05-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Aberrant DNA methylation is detected in pre- and postoperative blood samples and cancer and non-cancerous liver tissues.

Sponsors

Graduate School of Medicine, University of Tokyo
Lead Sponsor
Cancer Institute Hospital of Japanese Foundation for Cancer Research
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with liver cancer undergoing liver resection

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
Incidence of aberrant DNA methylation in peripheral blood and cancer tissues of liver cancer patients—

Countries

Japan

Contacts

Public ContactTakeaki Ishizawa

Graduate School of Medicine, University of Tokyo Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery

tish-tky@umin.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026